Association of drug effects on serum parathyroid hormone, phosphorus, and calcium levels with mortality in CKD: A meta-analysis

American Journal of Kidney Diseases

Volumn 66, Issue 6, 2015, Pages 962-971

  Palmer, Suetonia C ^a   Teixeira Pinto, Armando ^b   Saglimbene, Valeria ^c   Craig, Jonathan C ^b   Macaskill, Petra ^b   Tonelli, Marcello ^d   De Berardis, Giorgia ^e   Ruospo, Marinella ^c,f   Strippoli, Giovanni F M ^b,c,g  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Diaverum Medical Scientific Office   (Sweden)

^d UNIVERSITY OF CALGARY   (Canada)

^e Center for Outcomes Research and Clinical Epidemiology   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g UNIVERSITY OF BARI   (Italy)

Author keywords

all cause mortality; biomarker; bisphosphonates; calcimimetic agents; calcitonin; calcium; cardiovascular mortality; chronic kidney disease mineral and bone disorder (CKD MBD); death; dialysis; drug effect; meta analysis; outcomes; parathyroid hormone (PTH); phosphate binders; phosphorus; Renal failure; surrogate endpoint; Vitamin D compounds

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D DERIVATIVE; BIOLOGICAL MARKER; URINARY TRACT AGENT;

AGE; ARTICLE; BIOCHEMICAL ANALYSIS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER; COCHRANE LIBRARY; CORRELATIONAL STUDY; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; INTERVENTION STUDY; KIDNEY TRANSPLANTATION; MEDLINE; META ANALYSIS; METABOLIC BONE DISEASE; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAGING; SYSTEMATIC REVIEW; BLOOD; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; TRENDS;

BIOMARKERS; CALCIUM; HUMANS; MORTALITY; PARATHYROID HORMONE; PHOSPHORUS; RENAL AGENTS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84944132615     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.03.036     Document Type: Article

References (60)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 2013 1 150
2. G.A. Block, K. Martin, A. de Francisco, and et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 8 2004 350(15):1516-1525
3. L.Y. Agodoa, L. Appel, G.L. Bakris, and et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 21 2001 2719 2728
4. J.C. Peterson, S. Adler, J.M. Burkart, and et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 10 1995 754 762
5. A.S. Levey, L.A. Inker, K. Matsushita, and et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 6 2014 821 835
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
7. National Health Service England and Wales. Electronic drug tariff. http://www.ppa.org.uk/edt/July-2014/mindex.htm. Accessed July 23, 2014.
8. US Food and Drug Administration. Drug Approval Package: Renagel (sevelamer hydrochloride) capsules. Application no.: 020-926. http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/020926.cfm. Accessed July 23, 2014.
9. A.J. Collins, R.N. Foley, B. Chavers, and et al. US Renal Data System 2013 annual data report Am J Kidney Dis 63 1 suppl 1 2014 e1 e420
10. S.D. Navaneethan, S.C. Palmer, J.C. Craig, G.J. Elder, and G.F.M. Strippoli Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials Am J Kidney Dis 54 4 2009 619 637
11. S.C. Palmer, D.O. McGregor, P. Macaskill, J.C. Craig, G.J. Elder, and G.F.M. Strippoli Meta-analysis: vitamin D compounds in chronic kidney disease Ann Intern Med 147 12 2007 840 853
12. S.C. Palmer, A. Hayen, P. Macaskill, and et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis JAMA 305 11 2011 1119 1127
13. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement Ann Intern Med 151 4 2009 264 269
14. S. Palmer, D.O. McGregor, and G.F. Strippoli Interventions for preventing bone disease in kidney transplant recipients Cochrane Database Syst Rev 2 2005 CD005015
15. G.F. Strippoli, A. Tong, S.C. Palmer, G. Elder, and J.C. Craig Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Cochrane Database Syst Rev 4 2006 CD006254
16. S.C. Palmer, D.O. McGregor, J.C. Craig, G. Elder, P. Macaskill, and G.F. Strippoli Vitamin D compounds for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 4 2009 CD008175
17. S.C. Palmer, D.O. McGregor, J.C. Craig, G. Elder, P. Macaskill, and G.F. Strippoli Vitamin D compounds for people with chronic kidney disease requiring dialysis Cochrane Database Syst Rev 4 2009 CD005633
18. S.D. Navaneethan, S.C. Palmer, M. Vecchio, J.C. Craig, G.J. Elder, and G.F. Strippoli Phosphate binders for preventing and treating bone disease in chronic kidney disease patients Cochrane Database Syst Rev 2 2011 CD006023
19. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org.
20. R.D. Riley, J.R. Thompson, and K.R. Abrams An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown Biostatistics 9 1 2008 172 186
21. A. Gelman, and D.B. Rubin Markov chain Monte Carlo methods in biostatistics Stat Methods Med Res 5 4 1996 339 355
22. J.M. Bland, and D.G. Altman Bayesians and frequentists BMJ 317 7166 1998 1151 1160
23. D.V. Barreto, F.C. Barreto, A.B. de Carvalho, and et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study Nephron 110 4 2008 c273 c283
24. G.A. Block, D.M. Spiegel, J. Ehrlich, and et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis Kidney Int 68 4 2005 1815 1824
25. C. Charytan, J.W. Coburn, M. Chonchol, and et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis Am J Kidney Dis 46 1 2005 58 67
26. J.B. Chen, S.S. Chiang, H.C. Chen, and et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride Nephrology 16 8 2011 743 750
27. G.M. Chertow, S.K. Burke, P. Raggi Treat to Goal Working Group Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 1 2002 245 252
28. M. Chonchol, F. Locatelli, H.E. Abboud, and et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis Am J Kidney Dis 53 2 2009 197 207
29. J.W. Coburn, H.M. Maung, L. Elangovan, and et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4 Am J Kidney Dis 43 5 2004 877 890
30. D. Coyne, M. Acharya, P. Qiu, and et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD Am J Kidney Dis 47 2 2006 263 276
31. E.M. El-Shafey, A.E. Alsahow, K. Alsaran, A.A. Sabry, and M. Atia Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients Ther Apher Dial 15 6 2011 547 555
32. 2 as sole phosphate binder Nieren Hochdruckkrankheiten 22 1 1993 39 44
33. W. Grotz, C. Nagel, D. Poeschel, and et al. Effect of ibandronate on bone loss and renal function after kidney transplantation J Am Soc Nephrol 12 7 2001 1530 1537
34. W.H. Grotz, L.C. Rump, A. Niessen, and et al. Treatment of osteopenia and osteoporosis after kidney transplantation Transplantation 66 8 1998 1004 1008
35. M. Hayashi, Y. Tsuchiya, Y. Itaya, T. Takenaka, K. Kobayashi, and M. Yoshizawa Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial Nephrol Dial Transplant 19 8 2004 2067 2073
36. M. Ketteler, K.J. Martin, M. Wolf, and et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study Nephrol Dial Transplant 27 8 2012 3270 3278
37. J.S. Lindberg, B. Culleton, G. Wong, and et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 3 2005 800 807
38. H.H. Malluche, M.C. Monier-Faugere, G. Wang, and et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism Clin Nephrol 69 4 2008 269 278
39. D.E. Memmos, J.B. Eastwood, L.B. Talner, and et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis BMJ 282 6280 1981 1919 1924
40. P. Messa, F. Macário, M. Yaqoob, and et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism Clin J Am Soc Nephrol 3 1 2008 36 45
41. S.M. Moe, M. Zekonis, J. Harezlak, and et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol Am J Kidney Dis 38 4 2001 792 802
42. 3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients Bone 14 2 1993 125 131
43. J. Przedlacki, J. Manelius, and K. Huttunen Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure Nephron 69 4 1995 433 437
44. W. Qunibi, M. Moustafa, L.R. Muenz, and et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study Am J Kidney Dis 51 6 2008 952 965
45. W. Qunibi, W.C. Winkelmayer, R. Solomon, and et al. A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease BMC Nephrol 12 2011 9
46. T. Sadek, H. Mazouz, H. Bahlou, and et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study Nephrol Dial Transplant 18 3 2003 582 589
47. K.T. Smerud, S. Dolgos, I.C. Olsen, and et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation Am J Transplant 12 12 2012 3316 3325
48. G.B. Spasovski, A. Sikole, S. Gelev, and et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up Nephrol Dial Transplant 21 8 2006 2217 2224
49. W.N. Suki, R. Zabaneh, J.L. Cangiano, and et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients Kidney Int 72 9 2007 1130 1137
50. L.M. Ong, P. Narayanan, H.K. Goh, and et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism Nephrology 18 3 2013 194 200
51. P. Urena-Torres, I. Bridges, C. Christiano, and et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism Nephrol Dial Transplant 28 5 2013 1241 1254
52. A. Massart, F.D. Debelle, J. Racape, and et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial Am J Kidney Dis 64 5 2014 696 705
53. K. Yokoyama, H. Hirakata, T. Akiba, and et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD Clin J Am Soc Nephrol 9 3 2014 543 552
54. S.M. Moe, and N.X. Chen Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol 19 2 2008 213 216
55. A. Phrommintikul, S.J. Haas, M. Elsik, and H. Krum Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis Lancet 369 9559 2007 381 388
56. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 7 1996 605 613
57. S.A. Jamal, B. Vandermeer, P. Raggi, and et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Lancet 382 9900 2013 1268 1277
58. F.E. Murtagh, J. Addington-Hall, and I.J. Higginson The prevalence of symptoms in end-stage renal disease: a systematic review Adv Chronic Kidney Dis 14 1 2007 82 99
59. A. Tong, P. Sainsbury, S.M. Carter, and et al. Patients' priorities for health research: focus group study of patients with chronic kidney disease Nephrol Dial Transplant 23 10 2008 3206 3214
60. B. Manns, B. Hemmelgarn, E. Lillie, and et al. Setting research priorities for patients on or nearing dialysis Clin J Am Soc Nephrol 9 10 2014 1813 1821